The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Will The Market Value Of The Neurofibromatosis Type 1 Market Grow Between 2026 And 2030?
The market size for neurofibromatosis type 1 has witnessed substantial growth in recent years. It is projected to expand from $8.83 billion in 2025 to $9.68 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.6%. This historical growth can be attributed to several factors, including the early detection of nf1 symptoms, the emergence of pain management treatments, an uptick in the diagnosis of plexiform neurofibromas, the widespread adoption of surgical tumor removal procedures, and increasing awareness of genetic counseling.
The market for neurofibromatosis type 1 is projected to experience substantial expansion over the next few years. It is anticipated to grow to $13.78 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.2%. This growth throughout the forecast period can be attributed to factors such as the increasing demand for targeted NF1 therapies, rising investment in precision oncology, the widening array of optic glioma treatment options, enhanced availability of advanced imaging tools, and the emergence of novel gene-based treatments. Prominent trends identified for this period include a greater reliance on targeted therapy for tumor reduction, an escalating demand for early NF1 genetic testing, the expansion of surgical interventions for tumor removal, increased adoption of radiation therapy for optic gliomas, and a growing focus on supportive care and counseling services.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp
What Factors Are Contributing To The Growth Of The Neurofibromatosis Type 1 Market?
The neurofibromatosis type 1 (NF1) market is anticipated to grow, propelled by spontaneous (de novo) mutations. These mutations are genetic alterations that emerge for the first time in an individual due to errors in DNA replication or environmental factors, rather than being inherited from parents. The increase in spontaneous (de novo) mutations is linked to factors such as elevated parental age, environmental influences like radiation and chemical exposure, and inaccuracies during DNA replication in cell division. Neurofibromatosis type 1 (NF1) itself contributes to spontaneous (de novo) mutations due to the high mutation rate in its NF1 gene, which frequently undergoes significant deletions, insertions, or point mutations during gametogenesis, leading to new cases without a family history. As an illustration, a report published in August 2023 by Molecular Biology and Evolution, a US-based peer-reviewed journal, indicated that 1.17 million autosomal and pseudoautosomal variants, averaging 11,007 variants per offspring, successfully cleared the Mendelian violation filter. Among these, 534 putative de novo mutations (DNMs) were identified in POR and TVA families, excluding those shared between siblings. Thus, spontaneous (de novo) mutation is a significant driver of the neurofibromatosis type 1 (NF1) market’s growth.
How Is Segmentation Applied In The Neurofibromatosis Type 1 Market Segment Analysis?
The neurofibromatosis type 1 market covered in this report is segmented –
1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments
2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants
2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery
3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy
4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling
What Trends Are Shaping The Future Of The Neurofibromatosis Type 1 Market?
Major companies in the neurofibromatosis type 1 (NF1) market are concentrating on introducing advanced products like kinase inhibitors to enhance targeted treatment and patient outcomes. A kinase inhibitor refers to a drug that obstructs the activity of kinases, which are enzymes responsible for moving phosphate groups to proteins, thereby regulating various cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical company, obtained approval from China for Koselugo (selumetinib), used for treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval expands the availability of specific treatment options for pediatric NF1 patients, improving disease management and their quality of life. The introduction of Koselugo (selumetinib) in China aligns with the growing emphasis on precision medicine, offering a non-surgical alternative for managing inoperable plexiform neurofibromas.
Who Are The Companies Participating In The Neurofibromatosis Type 1 Market Environment?
Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals Incorporated, BeiGene Ltd, BioMarin Pharmaceutical Inc, Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc, CureAge Therapeutics, Fosun Pharmaceutical Group Co Ltd, AstraZeneca Plc, Genentech Inc, Regeneron Pharmaceuticals Inc, Amgen Inc, AbbVie Inc, GL Pharm Tech Corporation, ReCode Therapeutics Inc.
Get The Full Neurofibromatosis Type 1 Market Report:
https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report
Which Region Represents The Largest Share Of The Neurofibromatosis Type 1 Market?
North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neurofibromatosis Type 1 Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report
Browse Through More Reports Similar to the Global Neurofibromatosis Type 1 Market 2026, By The Business Research Company
Fibromyalgia Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report
Rare Neurological Disease Treatment Market Report
Uterine Fibroids Treatment Market Report
https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model